Facebook
X
LinkedIn
ForwardSouth Beach Symposium
General Session:
Persistent challenges in managing complex dermatologic conditions, including acne vulgaris, actinic keratosis, alopecia areata, atopic dermatitis, chronic hand eczema, chronic urticaria, hidradenitis suppurativa, melanoma, prurigo nodularis, psoriasis, psoriatic arthritis, seborrheic dermatitis, and acute/chronic wounds, necessitate comprehensive, contemporary education. This 24th annual South Beach Symposium is specifically designed to equip healthcare professionals with the critical, current knowledge required for optimizing patient outcomes by focusing on treatment guidelines and advanced diagnostic approaches, topline safety and efficacy data for the newest FDA-approved and emerging therapeutic agents, and expert consensus on designing personalized treatment plans to deliver best-in-class patient care. This curriculum will be delivered through an immersive, multi-format approach featuring expert-led panel discussions, hands-on workshops, live patient demonstrations, cutting-edge therapeutic updates, and interactive case-based discussions, all guided by the most renowned leaders in global dermatology practice and education.
Live Patient Injections Sessions:
The rapid pace of innovation in non-surgical facial and body rejuvenation, coupled with expanding therapeutic options, has created a critical need for practical, advanced training to ensure optimal patient outcomes and safety. Acknowledging this evolving aesthetic landscape, the 2026 South Beach Symposium will feature immersive live patient injection sessions. These sessions are designed to equip healthcare professionals with essential knowledge on the latest injection techniques and best practices for using toxins and dermal fillers, delivered through clinical insights and guidance from renowned industry experts. Participants will leave with the confidence and knowledge necessary for appropriate agent selection and precise execution of aesthetic treatments for their patients.
Image-Guided SRT: Advancing Non-Surgical Treatment of NMSC:
Non-melanoma skin cancers (NMSC), including basal cell carcinoma and squamous cell carcinoma, although less aggressive than melanoma, are the most prevalent human malignancies. Mohs micrographic surgery can achieve high cure rates, but requires precise assessment of the tumor margins, often with the naked eye or dermoscopy. Non-surgical, image-guided superficial radiation therapy (IG-SRT) has been developed as an alternative to Mohs micrographic surgery for NMSC. With this new technology, SRT is paired with high resolution dermal ultrasound to provide non-invasive treatment. Clinicians who specialize in dermatology are especially poised to diagnose, manage, and assess response to treatment for their patients with NMSC. This live, in-line session to be held at the 2026 South Beach Symposium annual meeting, will educate participants on the benefits and drawbacks of traditional vs non-invasive procedures, including the most recent clinical data and dermatology-focused considerations for the use of radiation therapy in the management of NMSC.
Expert Perspectives: Navigating Chronic Urticaria Care Today and Tomorrow:
The symptoms and management of chronic urticaria (CU) can present significant challenges for affected patients. Although antihistamines are the first-line option for patients with CU, many do not achieve adequate symptom control. Current treatments target histamine or autoantibodies, but novel therapies, such as Bruton’s tyrosine kinase inhibitors, are being developed. To effectively manage chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), HCPs require education on the recommendations for diagnosis and management of these conditions, as well as the clinical efficacy and safety of new and emerging treatments. This in-line session, presented during the 2026 South Beach Symposium, will provide learners with expert-guided instruction on the recognition and diagnosis of CSU/CIndU, as well as the most up-to-date clinical data for current and emerging targeted therapies to overcome unmet treatment needs.
Target Audience
The activity is designed for an audience of US-based physicians, nurses, advanced practice providers and professional staff members of medical practice specializing in dermatology.
Learning Objectives
General Session
- Integrate guideline-directed recommendations with clinical efficacy and safety data to select appropriate treatments for patients with acne vulgaris.
- Assess current evidence on the efficacy and safety of available and investigational therapies for actinic keratosis.
- Evaluate clinical evidence on approved and emerging therapies to guide treatment selection for patients with alopecia areata.
- Analyze the latest clinical efficacy and safety data for current and emerging treatments for atopic dermatitis.
- Interpret emerging clinical evidence on novel therapeutic agents for chronic hand eczema to inform evidence-based, disease subtype-inclusive management strategies, given the limitations of existing treatments.
- Review the evolving evidence base for current and investigational therapies in chronic urticaria to guide optimal, guideline-aligned treatment decisions.
- Apply current evidence to guide individualized treatment selection for patients with hidradenitis suppurativa, including targeted therapies that may alter disease progression and improve long-term outcomes.
- Examine current evidence and emerging clinical data to personalize melanoma treatment strategies by incorporating novel approaches into optimal therapeutic sequencing.
- Develop informed approaches based on emerging clinical data to guide the use of targeted therapies for patients with prurigo nodularis.
- Assess current clinical evidence to guide personalized treatment decisions for patients with psoriasis who require systemic therapy.
- Compare the efficacy and safety profiles of current and emerging therapies for psoriatic arthritis to guide treatment selection.
- Evaluate the efficacy and safety of current and emerging therapies for seborrheic dermatitis to inform optimal treatment selection, particularly in difficult-to-treat or hair-bearing areas.
- Analyze current and emerging strategies for wound care, with a focus on optimal healing with minimal scar formation.
Live Patient Injections Sessions
- Assess the efficacy, safety, and appropriate injection techniques for current and emerging soft tissue fillers and neuromodulators.
- Describe expert recommendations for technical approach and product selection to optimize aesthetic outcomes and minimize adverse events.
Image-Guided SRT: Advancing Non-Surgical Treatment of NMSC
- Critically assess clinical data regarding surgical and non-invasive procedural interventions for the treatment of NMSC
- Develop personalized management plans for NMSC, including appropriate integration of radiation therapy based on the needs of individual patients
Expert Perspectives: Navigating Chronic Urticaria Care Today and Tomorrow
- Distinguish the clinical features of chronic spontaneous urticaria, chronic inducible urticaria, and similar conditions to facilitate initiation of appropriate treatment.
- Critically analyze the clinical data for current and emerging targeted therapies for chronic urticaria to overcome treatment challenges.
Elevating Seborrheic Dermatitis Treatment: From Pathophysiology to PDE4 Inhibition and Targeted Care
- Demonstrate a comprehensive understanding of the underlying inflammatory drivers of seborrheic dermatitis to facilitate timely diagnosis and treatment.
- Integrate evidence-based treatment selection into seborrheic dermatitis management plans based on critical evaluation of clinical efficacy and safety data for new and emerging therapies, including PDE4 inhibitors.
Commercial Support
This activity is supported by educational grants from Almirall, LLC, Celltrion USA, Inc., Johnson & Johnson, and Organogenesis, Inc.
The live patient injection session is supported by in-kind grants from AbbVie, Inc., Evolus, Inc., Galderma Laboratories, L.P., Revance Therapeutics, Inc., and Merz North America, Inc.
Image-Guided SRT: Advancing Non-Surgical Treatment of NMSC session is supported by an educational grant from SkinCure.
Expert Perspectives: Navigating Chronic Urticaria Care Today and Tomorrow session is supported by an educational grant from Novartis Pharmaceuticals Corporation.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Adelaide Hebert, MD | Advisor | Pfizer, Arcutis, Incyte, Dermavant/Organon, Sun Pharma, Lilly, Ortho Dermatologics, Takeda, Oness |
Consultant | Pfizer, Arcutis, Dermavant, Organon/Dermavant, Incyte, Lilly, Takeda, Ortho Dermatologics, Galderma | |
Researcher | Pfizer, Organon, Oneness, Takeda, Janssen, Arcutis, Amgen, Abbvie, Galderma | |
Ahuva Cices, MD | Advisor | Novartis |
Antonio Torrelo, MD | Advisor | Lilly, Pfizer |
Speaker | Viatris, Lilly | |
Ayman Grada, MD | Employee | AbbVie - Medical Director |
Barry Resnick, MD | Consultant | Moonlake Pharmaceuticals, Incyte, Novartis, UCB |
Independent contractor (including contracted research) | Moonlake Pharmaceuticals | |
Speaker | Incyte, Novartis | |
Benjamin Ungar, MD | Consultant | AbbVie, Arcutis Biotherapeutics, Apogee Therapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Ebla Holdco, Galderma, J&J, Leo Pharma, Lilly, Nektar Therapeutics, Pfizer, Sanofi, Sun Pharma, Veradermics, VRG Therapeutics. |
Brian Berman, MD |
| Biofrontera, Advisory Board Honoraria Investigator PHD Biosciences, Honoraria Consultant, Thirona Bio, Consultant Honoraria Stock Options, SUN Pharmaceuticals, Inc Advisory Board & Consultant Honoraria, BPG Bio, Consultant, Honoraria Stock & Options, Exeltis, Consultant & Investigator Honoraria Ferndale Laboratories, Inc., Consultant Investigator Honoraria, FBM Therapeutics, Consultant Stock Options Galderma Laboratories, L.P. Advisory Board Honoraria GlaxoSmithKline, Consultant Honoraria, Minolabs, Consultant Honoraria Investigator Stock, LEO Pharma, US Speaker, Advisory Board & Investigator Honoraria, Medimetriks Pharmaceuticals Inc., Consultant Honoraria, Miragen, Consultant Honoraria Investigator, Sirnanomics, Consultant Honoraria, Pierre-Fabre, Consultant Honoraria, Pfizer, Consultant Honoraria, Castle, Consultant Honoraria, Lemonex, Consultant Honoraria, Pelthos, Consultant, Speaker Honoraria, Novartis Pharmaceuticals Corp., Advisory Board & Speaker Honoraria, Sonoma (Oculus Innovative Sciences, Inc.), Consultant Stock Options, Sensus, Speaker Consultant Honoraria Investigator, TopMD, Advisory Board Stock, Ortho Dermatologics/Valeant, International Speaker & Advisory Board, Cutanea, Advisory Board Honoraria, Birch BioMed, Advisory Board Honoraria, Encore Dermatology, Consultant Honoraria & Investigator, Aclaris, Consultant Honoraria, Aiviva, Consultant, Anacor Pharmaceuticals, Inc., Advisory Board & Investigator, Menlo Therapeutics, Consultant Honoraria & Investigator, BMS, Consultant, Pulse, Consultant Investigator, Almirall, Consultant, Speaker, Mediwound, Consultant Investigator |
Brian Hibler, MD | Consultant | Allergan Aesthetics, SharkNinja |
Individual stocks and stock options | Limax Biosciences, Dr. Kudos Lab | |
Speaker | Allergan Aesthetics, Sofwave | |
Cheri Frey, MD | Advisor | Kenvue, Johnson & Johnson, Abbvie, Crown Aesthetics, Biersdorf, Bubble, Incyte |
Consultant | Procter & Gamble, L'Oreal, Benev, Kenvue, Acclaro, Estee Lauder | |
Individual stocks and stock options | Xtresse | |
Researcher | Novartis, Reframe, Sanofi | |
Christopher Bunick, MD, PhD | Advisor | AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, Eli Lilly, EPI Health/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, UCB, and Veradermics. |
Consultant | AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, Eli Lilly, EPI Health/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, UCB, and Veradermics. | |
Researcher | AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda, Timber, and Palvella | |
David Cotter, MD, PhD |
| Abbvie, 2020-2025 General consulting on peer to peer education, marketing, and medical teams Education sessions for the medical science liaison teams Arcutis, 2023 Alumis, 2025 Blueprints in Medicine, 2025 Castle Biosciences, 2021-2025 o Consults on payer relations o Administers advisory boards o Conducts trainings for new sales associates and other employees o Faculty trainer for speakers bureau Bristol Myers Squibb, 2023, 2024, 2025 o Champions in Healthcare panelist at BMS headquarters, 2025 Boehringer Ingelheim, 2022-2025 Dermavant (now Organon), 2024- 2025 o Recorded podcast style educational content for internal use to assist in educating Dermavant employees on atopic dermatitis. Eli-Lilly, 2026 Johnson and Johnson, 2023-2025 o Icotrakinra steering committee Incyte 2025 LEO Adbry and delgocitinib, 2022-2025 o Board of Dermatology Member, 2023-present Novartis, 2024-2025 o General consulting on peer to peer education, marketing, and medical teams for CSU, PsO, PsA, and HS o For PsO and PsA, in 2024 I was part of an expert consensus article that will include videos of me offering advice on how to screen for PsA in the dermatology clinic. Expected release date will be 2025. Pfizer, 2024-2025 Sanofi-Regeneron, 2019-2020 UCB, 2024-2025 o General consulting on peer to peer education, marketing, and medical teams for PsO, PsA, and HS Abbvie, 2020-2025 Principal Investigator, Castle Biosciences, ALIGN-AD. 2026- Present Principal Investigator, LEO, REAl-Word Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment with Delgocitinib cream in North America (REACHED-NA). 2026-present. Principal Investigator, Abbvie, M23-716 study, A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata. October 2025-present. Principal Investigator, Novartis, REASSERT study (CLOU064A2402), Remibrutinib in real-world clinical practice: a prospective, multi-country, non-interventional, effectiveness and safety study (REASSERT). Sept 2025-present. Principal Investigator, Regeneron, Regeneron Protocol: R2810-ONC-225; CRO Study #: 0456-0716; Protocol Title: A PHASE 3 RANDOMIZED STUDY OF INTRALESIONAL CEMIPLIMAB VERSUS PRIMARY SURGERY IN PARTICIPANTS WITH EARLY STAGE CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC). April 2025-present. Principal Investigator, Novartis, CLOU064AUS02 RECLAIM trial. A US Phase 3b, Multi-center, Randomized, Double-blind, Double Dummy Study Demonstrating Superiority of Remibrutinib to Dupilumab at Early Timepoints in Adults with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines. March 2025-Present. Principal investigator, Adelphi AG9909 study, Clinical Characteristics, Treatment Patterns and Outcomes in Patients with Alopecia Areata Following Initiation of Ritlecitinib, Baricitinib, or Standard of Care Treatment. Non-interventional prospective chart study (with elements of retrospective data collection), March 2025-Present. Principal Investigator, Abbvie M23-698 study, A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. November 2024-Present. Sub Investigator, Novartis, CGIA632B12201: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period Sub Investigator, Sanofi, OBS18388 / LAB12293, Atopic deRMAtitis DiseAse registry of ADult and adolescent patients initiating or switching systemic treatments (ARMADA-AD) Sub-Investigator, Eli Lilly, I1F-MC-RHDC; Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO). 2024-present. Sub-Investigator, Sanofi, OBS17721; A Prospective Observational Study of Patients Receiving Dupilumab for Prurigo Nodularis, 2023-present. Sub-Investigator, Dermavant, Feb 2023-June 2023. Closed. Principal Investigator, Castle Biosciences, IDENTITY Study. August 2021-March 2025. Closed Sub-Investigator, Castle Biosciences, Protocol Number: CBI_2019_cSCC_PVS_001- Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma; 5/2020-2023. Closed. Sub-Investigator, Galderma, Protocol No.: RD.06.SPR.118380- A Randomized, Double-Blind, Placebo- Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects with Moderate-to- Severe Atopic Dermatitis Treated with Nemolizumab; 5/2020-2022. Closed. Sub-Investigator, Corevitas, Psoriasis registry, 2019- present Sub-Investigator, Celgene, Phase IV Oral Apremilast for Genital psoriasis; 7/2019- Dec 2021. Closed Sub-Investigator, Novartis, Protocol Number: CAIN457S12201 - A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled with topical therapies-PRELUDE; 2020- 2022. Closed. Sub-Investigator, PROSE Study, Phase IV Observational Registry for Dupixent for Atopic Dermatitis; 1/2020-close of study. Abbvie, January 2021-present o Humira, Skyrizi, Rinvoq o National Speaker, 2024 to present Arcutis, 2024- present, Atopic Dermatitis, Psoriasis, and Seborrheic Dermatitis o Local and regional speaker programs, and national webinars Boehringer Ingelheim, 2022-2025 (ended as BI transferred derm IP to LEO) Bristol Myers Squibb January 2024-present Castle Biosciences, October 2020-present o National Speaker, 2022-present Dermavant/ Organon, 2024 to present, Atopic Dermatitis and Psoriasis DermTech, 2022-2024 Galderma, November 2020-present o Acne and Rosacea, 2020-present o Cetaphil, 2024-present o Nemolizumab, Prurigo Nodularis and Atopic Dermatitis, 2024-present Journey, December 2020-2022 LEO, September 2023-present Novartis. 2025-present Sanofi, May 2023-present, Atopic Dermatitis, Prurigo Nodularis, Chronic Spontaneous Urticaria, Bullous Pemphigoid o National speaker Regeneron, May 2023-present, Atopic Dermatitis, Prurigo Nodularis, Chronic Spontaneous Urticaria, Bullous Pemphigoid VYNE, 2021-2022 |
David Goldberg, MD, JD | Consultant | Absci, Veradermics, Artemis, Aerolase, Focus |
Researcher | Focus, Veradermics, Allergan , Sun | |
Diego Dasilva, MD | Advisor, Consultant & Speaker | AbbVie, Pfizer, Leo, Galderma, UCB, Lilly, Arcutis, Organon, Sanofi/Regeneron |
Gil Yosipovich, MD | Advisor | Abbvie, Arcutis,.Almiral, Amgen, Attovia , Behringer Ingelheim, Celldex, Escient Health, Eli Lilly, Galderma,, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, , Vifor, GSK, Celldex, – advisory board member consultant |
Researcher | Investigator Research support Eli Lilly,, LEO Pharma, Novartis, Pfizer, Galderma, Escient, Clexio, Regeneron, Sanofi, Celldex ,Kiniksa , Pfizer, Abbvie | |
Glynis Ablon, MD | Researcher | Nutrafol, Benev, Church Dwight, Galderma |
Heather Woolery-Lloyd, MD | Researcher | AbbVie, Allergan, Eirion Therapeutics, Regeneron, Galderma, Pfizer, Arcutis, Teoxane Laboratories, Avita Medical, Kymera |
Jennifer Hsiao, MD | Consultant/Advisory board | AbbVie, Aclaris, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Leo Pharma, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Regeneron, UCB |
Researcher/Investigator | Amgen, AstraZeneca, Incyte, Novartis | |
Speaker | AbbVie, Galderma, Novartis, Sanofi, Regeneron, UCB | |
Joel Claveau, MD | Advisor, Speaker, Consultant | BMS, Merck, Novartis, Pfizer, Regeneron |
Researcher | BMS, Merck, Regeneron | |
Karan Lal, DO | Consultant | Sanofi, Abbvie |
Speaker | Abbvie, Galderma, Pfizer, Amgen, Sanofi, Regeneron, Incyte, Botanix, Sun, Aerolase, Lilly | |
Lawrence Green, MD | Advisor | Pelthos, Takeda, Alphyn, Revance, Kenvue, Feldan, Veradermics |
Researcher | Takeda, Oruka, Apogee, Incyte, Veradermics, Pfizer, Janssen | |
Speaker | Incyte, Galderma, UCB, Organon | |
Leon Kircik, MD | Advisory Board | Aclaris, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Arcutis, Arena, Biogen-Idec, BMS, Cassiopea, Cipher, Colbar, Connetics Corporation, Dermavant, Dermira, EOS, Dr. Reddy’s Lab, Ferndale Laboratories, Inc., Foamix, Eli Lilly, Exeltis, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Glenmark, Incyte, Innocutis, Isdin, Johnson & Johnson, Nano Bio, Novartis AG, Promius, Quinnova, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott |
Consultant | Abbvie, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Arcutis, BMS, Cassiopea, Cipher, Colbar, Connetics Corporation, Dermavant, Dermira, Dr. Reddy’s Lab, Ferrer, Eli Lilly, Exeltis, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Isdin, Johnson & Johnson, Laboratory Skin Care Inc., Leo, Medical International Technologies, Merck, Merz, Novartis AG, Promius, PuraCap, Rapt, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, UCB, Valeant Pharmaceuticals Intl, ZAGE | |
Investigator | Abbvie, Ablynx, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Astellas Pharma US, Inc., Astellas Pharma US, Inc., Asubio, Bausch Health, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biolife, BioMimetix, Biopelle, BMS, Boehringer-Ingleheim, Breckinridge Pharma, Centocor, Inc., Cellceutix, Coherus, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dow Pharmaceutical Sciences, Inc., Dr. Reddy’s Lab, Dusa, Ferndale Laboratories, Inc., Foamix, Eli Lilly, Exeltis, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Glenmark, Health Point, LTD, Idera, Incyte, Intendis, Johnson & Johnson, Leo, L’Oreal, 3M, Maruho, Merck, Medicis Pharmaceutical Corp., Nano Bio, Nektar, Nimbus, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Pfizer, Promius, PharmaDerm, QLT, Inc, Quinnova, Quatrix, Rapt, Regeneron, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, TolerRx, UCB, Valeant Pharmaceuticals Intl, Ventyx, Warner-Chilcott, XenoPort | |
Speaker | Abbott Laboratories, Allergan, Inc., Almirall, Amgen, Inc., Assos Pharma, Astellas Pharma US, Inc., Assos Pharma, Astellas Pharma US, Inc., Cipher, Connetics Corporation, Dermavant, Dermira, Dermik Laboratories, Embil Pharmaceuticals, Ferrer, Eli Lilly, Exeltis, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Innocutis, Innovail, Isdin, Johnson & Johnson, Kyowakirin, Leo, L’Oreal, 3M, Novartis AG, Onset, PediaPharma, PharmaDerm, Regeneron, Sanofi, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, Triax, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott | |
Michael Gold, MD | Consultant | Speaker/consultant: Acclaro, Aerolase, Aesthetic Management Partners, Aesthetic Bio Medical, Alastin/Galdrma, Allergan, Alma Lasers, Bausch Health, Benev/Exocobio, Cutera, EndyMed, Exocobio,Hugel, InMode, La Mer, Lumenis, Merz, Mindera, MTF, Nutrafol, Pierre Fabre / Glytone, Prescribers Choice, Revance, Revision Skin Care, Sciton, Sensus, Senté, Skinbetter Science, SkinCeuticals, Skin Medica, SKNV, Sofwave, Stratpharma, Venus Concept, VIOL |
Researcher | Research: Alma Lasers, Bausch Health, Benev, Galderma, Hugel, Leo Pharma, Lumenis, Merz, MTF, Nutrafol, Revance, Revision Skin Care, Skinbetter Science, Skin Medica, Sofwave | |
Mohamad Goldust, MD | N/A | Nothing to disclose |
Mona Shahriari, MD | Consultant | AbbVie, Alumis, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Organon, Galderma, Pfizer, Incyte, Janssen, Leo Pharma, Lilly USA, Novartis, Sanofi-Genzyme, Regeneron, Takeda, UCB |
Researcher | CorEvitas Psoriasis and Atopic Dermatitis Registry, Incyte, Takeda, Abbvie, Oruka | |
Speaker | Abbvie, Arcutis, Bristol Myers Squibb, Galderma, Lilly USA, Incyte, Janssen, Organon, Novartis, Pfizer, Galderma, UCB, Sanofi, Regeneron | |
Neal Bhatia, MD | Advisor | Abbvie, Advanced Derm Solutions, Almirall, Alumis, Apogee, Arcutis, Beiersdorf, Biofrontera, Botanix, Celldex, Galderma, J&J, Journey, LaRoche-Posay, LEO, Lilly, Novartis, Ortho, Pfizer, Regeneron, Sagimet, Sanofi, SkinFix, Soligenix, SunPharma, Takeda, Veradermics, and Verrica |
Consultant | Abbvie, Advanced Derm Solutions, Almirall, Alumis, Apogee, Arcutis, Beiersdorf, Biofrontera, Botanix, Celldex, Galderma, J&J, Journey, LaRoche-Posay, LEO, Lilly, Novartis, Ortho, Pfizer, Regeneron, Sagimet, Sanofi, SkinFix, Soligenix, SunPharma, Takeda, Veradermics, and Verrica | |
Researcher | Abbvie, Advanced Derm Solutions, Almirall, Alumis, Apogee, Arcutis, Beiersdorf, Biofrontera, Botanix, Celldex, Galderma, J&J, Journey, LaRoche-Posay, LEO, Lilly, Novartis, Ortho, Pfizer, Regeneron, Sagimet, Sanofi, SkinFix, Soligenix, SunPharma, Takeda, Veradermics, and Verrica | |
Speaker | Abbvie, Galderma,LaRoche-Posay, LEO, Novartis, Ortho, Pfizer, SunPharma, | |
Patricia Farris, MD | Advisor | Alumier MD, Amlactin, Bubble Skincare, Galderma, Kenvue, La Roche Posay, L'Oreal, Nutraceutical Wellness, RegimenMD, Skinceuticals, Skinbetter Science, Vichy |
Consultant | Alumier MD, Kenvue, L'Oreal, Nutraceutical Wellness, RegimenMD | |
Peter Lio, MD | Advisor | Alphyn Biologics, AbbVie, Almirall, Amyris, Apogee, Arcutis, ASLAN, Astria Therapeutics, Boston Skin Science, Bristol-Myers Squibb, Burts Bees, Castle Biosciences, Codex Labs, Concerto Biosci, ClearRx, Dermavant, Eli Lilly, Galderma, Kenvue, LEO Pharma, Lipidor, L'Oreal, Merck, Midwest Bioprocessing, Micreos, MyOR Diagnostics, Nektar Therapeutics, Nia Health, Pelthos Therapeutics, Phyla, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Soteri Skin, Stratum Biosciences, Sun Pharma, Theraplex, Thimble Health, Topaz Biosciences,Inc., UCB, Unilever, Verdant Scientific, Verrica, Yobee Care |
Individual stocks and stock options | Alphyn Labs, Codex Labs, Concerto Biosci, Midwest Bioprocessing, Soteri Skin, Stratum Biosciences, Topaz Biosciences, Inc., Yobee Care, Verdant Scientific | |
Royalties or patent beneficiary | Theraplex AIM - Theraplex | |
Speaker | AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L'Oreal, MyOR Diagnostics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Verrica | |
Randy Miller, MD | N/A | Nothing to disclose |
Roberta Del Campo, MD | N/A | Nothing to disclose |
Ruth Ann Vleugels, MD | Consultant | Priovant, AstraZeneca, Bristol Myers BMS, Lilly, AbbVie, Apogee |
Susan Weinkle, MD | Advisor | Allergan, Merz |
Consultant | Allergan, Galderma, Merz, Teoxane, Evolus, Revance | |
Individual stocks and stock options | Derm Avance | |
Speaker | Allergan, Galderma | |
Ted Lain, MD | Advisor, Consultant, Independent contractor (including contracted research) | Almirall, Biofrontera |
Speaker | Almirall | |
Todd Schlesinger, MD | Investigator and/or Consultan | AbbVie, Almirall, Apogee, Arcutis Biotherapeutics, Benev, Biofrontera, Bristol Myers Squibb, Crown Aesthetics, Eli Lilly, Flint Clinical, Genentech, Janssen, LEO Pharma, Oruka, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Verrica, and UCB; has served as an investigator for AbbVie, Allergan, Almirall, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Biofrontera, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Concert Pharmaceuticals (acquired by Sun Pharma), Cutanea Life Sciences, Dermavant Sciences, Eli Lilly, Galderma, Highlightll, Incyte, Janssen, Nimbus Therapeutics, Medicus, Novartis, Processa, Prolacta, Regeneron Pharmaceuticals, Sanofi, SkinCure Oncology, Takeda, Trevi Pharmaceuticals, and Verrica |
Shareholder | Bristol Myers Squibb, Chronicle Medical Software, Eli Lilly, and Remedly | |
Z. Paul Lorenc, MD | N/A | Nothing to disclose |
Dorothy Caputo, MA, BSN, RN, President | N/A | Nothing to disclose |
Rebecca Lakofsky, BSN, RN | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 16.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Credit being awarded: 16.75 ANCC contact hours
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 16.75 AAPA Category 1 CME
- 16.75 AMA PRA Category 1 Credit™
- 16.75 ANCC
- 16.75 Attendance